Why the study?
Immune checkpoint inhibitors are increasingly used in combination for cancer therapy but cause myocarditis, with emerging clinical data and genetic models suggesting female susceptibility through unknown mechanisms.
Do hormonal therapies or recombinant MANF protein attenuate immune checkpoint inhibitor-associated myocarditis in preclinical models?
Do hormonal therapies or recombinant MANF protein attenuate immune checkpoint inhibitor-associated myocarditis in preclinical models?
Hormonal therapies and MANF administration attenuate ICI-induced myocarditis in preclinical models, revealing an endocrine-cardiac-immune pathway that explains female susceptibility to this toxicity.
Answers are grounded in this paper and cite their sources.
These preclinical findings do not support clinical use of hormonal or MANF therapies in ICI-myocarditis; leaves open translation of endocrine-immune pathways to human cardiotoxicity.
Immune checkpoint inhibitors (ICIs) have been increasingly used in combination for cancer treatment but are associated with myocarditis. Here, we report that tumor-bearing mice exhibited response to treatment with combinatorial anti-programmed cell death 1 and anti-cytotoxic T lymphocyte antigen-4 antibodies but also presented with cardiovascular toxicities observed clinically with ICI therapy, including myocarditis and arrhythmia. Female mice were preferentially affected with myocarditis compared to male mice, consistent with a previously described genetic model of ICI myocarditis and emerging clinical data. Mechanistically, myocardial tissue from ICI-treated mice, the genetic mouse model, and human heart tissue from affected patients with ICI myocarditis all exhibited down-regulation of MANF (mesencephalic astrocyte-derived neurotrophic factor) and HSPA5 (heat shock 70-kDa protein 5) in the heart; this down-regulation was particularly notable in female mice. ICI myocarditis was amplified by heart-specific genetic deletion of mouse Manf and was attenuated by administration of recombinant MANF protein, suggesting a causal role. Ironically, both MANF and HSPA5 were transcriptionally induced by liganded estrogen receptor β and inhibited by androgen receptor. However, ICI treatment reduced serum estradiol concentration to a greater extent in female compared to male mice. Treatment with an estrogen receptor β-specific agonist and androgen depletion therapy attenuated ICI-associated cardiac effects. Together, our data suggest that ICI treatment inhibits estradiol-dependent expression of MANF/HSPA5 in the heart, curtailing the cardiomyocyte response to immune injury. This endocrine-cardiac-immune pathway offers new insights into the mechanisms of sex differences in cardiac disease and may offer treatment strategies for ICI myocarditis.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: